Headlands Technologies LLC Increases Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)

Headlands Technologies LLC grew its stake in BeiGene, Ltd. (NASDAQ:BGNE) by 761.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,773 shares of the company’s stock after acquiring an additional 2,451 shares during the period. Headlands Technologies LLC’s holdings in BeiGene were worth $396,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Capital International Investors raised its position in BeiGene by 11.5% in the first quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after purchasing an additional 727,556 shares during the period. First Trust Advisors LP acquired a new position in BeiGene during the 4th quarter worth about $39,632,000. M&G Plc acquired a new position in BeiGene during the 1st quarter worth about $29,649,000. Goldman Sachs Group Inc. boosted its holdings in BeiGene by 175.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after acquiring an additional 136,458 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after acquiring an additional 117,905 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BGNE has been the topic of several research reports. Citigroup increased their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America reduced their target price on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. Finally, JPMorgan Chase & Co. boosted their price target on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $233.42.

Insider Transactions at BeiGene

In related news, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $160.57, for a total transaction of $133,915.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other BeiGene news, CEO John Oyler sold 2,789 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $159.58, for a total transaction of $445,068.62. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total value of $133,915.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,210 shares of company stock valued at $2,269,721. 7.43% of the stock is currently owned by corporate insiders.

BeiGene Trading Down 7.0 %

NASDAQ BGNE opened at $196.27 on Friday. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $215.00. The firm has a 50 day moving average of $175.16 and a two-hundred day moving average of $163.01. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $19.02 billion, a PE ratio of -26.10 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The firm had revenue of $929.20 million during the quarter, compared to the consensus estimate of $810.34 million. During the same quarter in the previous year, the firm posted ($3.64) earnings per share. The company’s revenue was up 56.1% compared to the same quarter last year. As a group, research analysts expect that BeiGene, Ltd. will post -5.13 EPS for the current fiscal year.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.